June 11, 2008 - (BRONX,NY) - Researchers at University of Pittsburgh and Albert Einstein College of Medicine of Yeshiva University have discovered that the bacteria behind tuberculosis can grow on surfaces and that drug-tolerant strains flourish in these bacterial communities, the research team recently reported in Molecular Microbiology. The findings suggest a possible reason why human tuberculosis (TB) requires months of intensive antibiotic treatment and indicate a potential cause of the relapses that can nonetheless occur.
The researchers are the first to show that Mycobacterium tuberculosis can grow in surface-level bacteria clusters known as biofilms that are common in nature but never before shown for TB bacteria, explained the paper's senior author Graham Hatfull, chair and Eberly Family Professor of Biological Sciences in Pitt's School of Arts and Sciences. Hatfull collaborated and coauthored the paper with William Jacobs Jr., a Howard Hughes Medical Institute investigator and professor of microbiology and immunology at Einstein.
Hatfull, Jacobs, and their colleagues found that the biofilm bacteria are physiologically and genetically different from TB bacteria harvested in a lab—the type used in developing antibiotics. These variations result in a population of the bacteria that are "drug-tolerant and harbor persistent cells that survive high concentrations of anti-tuberculosis antibiotics," the team reports.
People with TB typically undergo six to nine months of treatment with multiple antibiotics and most of the bacteria generally die within the first two weeks. Yet the disease can recur, presumably because of drug-tolerant bacteria that have escaped the antibiotic. The source and location of these persistent cells are unknown, but Hatfull and Jacobs' research reveals a possible biofilm origin, Jacobs said.
"The nature of persisting M. tuberculosis cells has been an enigma for the entire field," Jacobs said. "Clearly M. tuberculosis cells in biofilms represent at least one class of persistent cells, and we are testing their biological relevance."
It is not yet known whether the biofilm actually factors into human TB infections, Hatfull said. He added that the only similar research regarding biofilm in living creatures showed the presence of biofilm-like or biofilm-related bacteria in guinea pigs.
"While our data does not show conclusively that biofilm formation in people gives rise to a drug-tolerant population, the fact that biofilms do so in the lab makes this an interesting and testable hypothesis," Hatfull said.
Other collaborators on the project include: Yann Guerardel and associate Xavier Trivelli of the Universite des Sciences et Technologies de Lille in France; Laurent Kremer and associate Anuradha Alahari of France's University of Montpellier; Pitt postdoctoral researcher Anil Ojha; and Jacobs' research associates Anthony Baughn, Dhinakaran Sambandan, and Tsungda Hsu.
The full paper can be read on the Molecular Microbiology Web site at www.blackwell-synergy.com/doi/full/10.1111/j.1365-2958.2008.06274.x